
Arcus Biosciences, Inc.
NYSE:RCUS
10.59 (USD) • At close August 29, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
---|---|---|---|---|---|---|---|---|---|
Revenue
| 258 | 117 | 112 | 383 | 78 | 15 | 8.353 | 1.413 | 0 |
Cost of Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.314 |
Gross Profit
| 258 | 117 | 112 | 383 | 78 | 15 | 8.353 | 1.413 | -1.314 |
Gross Profit Ratio
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
Reseach & Development Expenses
| 448 | 340 | 288 | 257 | 159 | 78.481 | 49.646 | 47.218 | 14.247 |
General & Administrative Expenses
| 120 | 117 | 104 | 72 | 43 | 25.228 | 13.566 | 7.636 | 3.935 |
Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SG&A
| 120 | 117 | 104 | 72 | 43 | 25.228 | 13.566 | 7.636 | 3.935 |
Other Expenses
| 20 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Expenses
| 588 | 457 | 392 | 329 | 202 | 103.709 | 63.212 | 54.854 | 18.182 |
Operating Income
| -330 | -340 | -280 | 54 | -124 | -88.709 | -54.859 | -53.441 | -18.182 |
Operating Income Ratio
| -1.279 | -2.906 | -2.5 | 0.141 | -1.59 | -5.914 | -6.568 | -37.821 | 0 |
Total Other Income Expenses Net
| 47 | 39 | 14 | 1 | 1 | 3.999 | 5.265 | 0.359 | 0.212 |
Income Before Tax
| -283 | -301 | -266 | 55 | -123 | -84.71 | -49.594 | -53.082 | -17.97 |
Income Before Tax Ratio
| -1.097 | -2.573 | -2.375 | 0.144 | -1.577 | -5.647 | -5.937 | -37.567 | 0 |
Income Tax Expense
| 1 | 6 | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
Net Income
| -283 | -307 | -267 | 53 | -123 | -84.71 | -49.594 | -53.082 | -17.97 |
Net Income Ratio
| -1.097 | -2.624 | -2.384 | 0.138 | -1.577 | -5.647 | -5.937 | -37.567 | 0 |
EPS
| -3.14 | -4.15 | -3.71 | 0.76 | -2.13 | -1.73 | -1.43 | -2.16 | -0.73 |
EPS Diluted
| -3.14 | -4.15 | -3.71 | 0.71 | -2.13 | -1.73 | -1.43 | -2.16 | -0.73 |
EBITDA
| -269 | -291 | -258 | 59 | -120 | -81.132 | -51.195 | -50.829 | -16.868 |
EBITDA Ratio
| -1.043 | -2.487 | -2.304 | 0.154 | -1.538 | -5.409 | -6.129 | -35.972 | 0 |